Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
- Editor
- Feb 13
- 1 min read
Whats Happening:
Newronika, a leader in advanced deep brain stimulation, has successfully closed a €13.6 million Series B funding round. The financing was led by new investor Fondazione ENEA Tech e Biomedical, with participation from existing investors. This funding will support the expansion of clinical validation and commercialization of Newronika's proprietary adaptive DBS system for Parkinson's disease patients.
Key Moves:
Newronika closes €13.6 million Series B funding round
Funding led by new investor Fondazione ENEA Tech e Biomedical
Capital to support clinical validation and commercialization of adaptive DBS system
By The Numbers:
€13.6 million raised in Series B funding
Newronika aims to improve symptom relief and reduce side effects for Parkinson's patients
Company recently received IDE approval from FDA
Key Quotes:
"This Series B round validates our commitment to transform the way deep brain stimulation is delivered," said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika.
"We see extraordinary potential to revolutionize the treatment of movement disorders on a global scale," said Maria Cristina Porta, ENEA Tech e Biomedical General Manager.
"Indaco is proud to continue supporting Newronika in the upcoming clinical and commercial phases," said Davide Turco, CEO of Indaco.
Bottom Line:
Newronika's successful Series B funding round positions the fund to accelerate the development and commercialization of its adaptive DBS platform. With strong investor support and recent regulatory milestones, Newronika is poised to advance its mission of transforming neuromodulation therapy for Parkinson's disease patients.
Comments